Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 10.8% – What’s Next?

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) rose 10.8% on Tuesday . The company traded as high as $10.86 and last traded at $10.54. Approximately 41,619 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 467,094 shares. The stock had previously closed at $9.51.

Analysts Set New Price Targets

A number of equities research analysts recently commented on BCAX shares. HC Wainwright decreased their target price on Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a report on Monday. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a report on Thursday, March 27th. Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a report on Thursday, March 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $36.50.

Bicara Therapeutics Trading Up 4.0 %

The business has a 50-day simple moving average of $13.03 and a 200-day simple moving average of $17.36.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). As a group, equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new stake in Bicara Therapeutics in the 4th quarter worth about $25,000. Spire Wealth Management acquired a new position in shares of Bicara Therapeutics during the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets purchased a new position in shares of Bicara Therapeutics in the fourth quarter valued at approximately $32,000. Legal & General Group Plc acquired a new stake in shares of Bicara Therapeutics in the fourth quarter worth approximately $33,000. Finally, Summit Investment Advisors Inc. purchased a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $35,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.